Abstract
Aim: The present study, using the histoculture drug response assay (HDRA) compared chemosensitivity with the clinical response of a treatment regime in patients with advanced colorectal cancer (CRC). Patients and Methods: A total of 324 patients with primary CRC were prospectively enrolled. HDRAs were performed using seven combinations of anticancer drugs, including 5-fluorouracil with leucovorin (FL), FL with oxaliplatin (FOLFOX), irinotecan (FOLFIRI), and their combinations with bevacizumab and cetuximab. Results: Among 324 HDRA results, tumor inhibition rates of regimes using FOLFOX (34.2-39.2%) were higher than those using FOLFIRI (24.2-32.7%, p<0.001). Out of 86 evaluated chemotherapeutic regimes, the correlation rate of HDRA to the clinical effect of chemotherapy was calculated to be 66.3% (57/86), with a 72.7% (40/55) sensitivity and a 54.7% (17/31) specificity. Conclusion: HDRA might be a feasible and useful technique for predicting therapy efficacy and selecting the appropriate anticancer regime for individual patients, notwithstanding its low accuracy.
| Original language | English |
|---|---|
| Pages (from-to) | 3581-3586 |
| Number of pages | 6 |
| Journal | Anticancer Research |
| Volume | 32 |
| Issue number | 8 |
| State | Published - Aug 2012 |
Keywords
- Chemotherapy
- Colorectal adenocarcinomas
- Histoculture drug response assay (HDRA)
- Molecular targeted therapy
- Treatment outcome
